Phase I Dose-Escalation Study of Docetaxel Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma

摘要

A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal carcinoma were enrolled and received DCF combination therapy at different dose levels. DLTs included febrile neutropenia and oral mucositis. DLT occurred in 2 out of 6 patients at level 2 and 3. The study proceeded to level 4, according to the protocol. The level 4 dose was defined as the MTD and the level 3 dose was defined as the RD. The RD for DCF combination chemotherapy for advanced esophageal carcinoma in the present study was 70 mg/m² DOC plus 70 mg/m² CDDP on day 1 plus 700 mg/m² 5-FU on days 1–5 at 4-week intervals. This regimen was tolerable and highly active. A phase II study has been started.